Friedreich Ataxia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Friedreich Ataxia Clinical Trials Market Report Overview
The Friedreich Ataxia clinical trial market research report provides an overview of the Friedreich Ataxia clinical trials scenario. The report provides top-line data relating to the clinical trials on Friedreich Ataxia. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Friedreich Ataxia Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Friedreich Ataxia clinical trials market are North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America, among others. North America dominates the market.
In a country-wise analysis, as of January 2023, the US has the highest number of Friedreich Ataxia clinical trials, followed by Italy, France, Spain, Austria, Germany, the UK, Australia, Belgium, and the Netherlands.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Italy has the highest proportion of Friedreich Ataxia to Central Nervous System clinical trials as of January 2023. Also, most of the clinical trials were conducted in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil has the highest proportion of Friedreich Ataxia to Central Nervous System clinical trials as of January 2023. Out of all the clinical trials conducted in the E7 countries, the majority were in Brazil.
Friedreich Ataxia Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the Friedreich Ataxia clinical trials market, download a free report sample
Friedreich Ataxia Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Friedreich Ataxia clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominated the market.
Friedreich Ataxia Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the Friedreich Ataxia clinical trials market, download a free report sample
Friedreich Ataxia Clinical Trials Market - Competitive Landscape
The leading sponsors in the Friedreich Ataxia clinical trials market are Santhera Pharmaceuticals Holding AG, PTC Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Clinilabs Inc, Ixchel Pharma LLC, Larimar Therapeutics Inc, Neurocrine Biosciences Inc, Ataxia UK, Horizon Therapeutics Plc, and Reata Pharmaceuticals Inc. Out of them, Santhera Pharmaceuticals Holding AG has conducted the highest number of Friedreich Ataxia clinical trials.
Friedreich Ataxia Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading players in the Friedreich Ataxia clinical trials market, download a free report sample
Friedreich Ataxia Clinical Trials Market Report Overview
Key Regions | Asia-Pacific, North America, Europe, Middle East & Africa, and South & Central America |
Key Countries | The US, Italy, France, Spain, Austria, Germany, the UK, Australia, Belgium, and the Netherlands |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Santhera Pharmaceuticals Holding AG, PTC Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Clinilabs Inc, Ixchel Pharma LLC, Larimar Therapeutics Inc, Neurocrine Biosciences Inc, Ataxia UK, Horizon Therapeutics Plc, and Reata Pharmaceuticals Inc |
Segments Covered in the Report
Friedreich Ataxia Clinical Trials Regional Outlook (2023)
- North America
- Europe
- Asia-Pacific
- Middle East & Africa
- South & Central America
Friedreich Ataxia Clinical Trials Country Outlook (2023)
- The US
- Italy
- France
- Spain
- Austria
- Germany
- The UK
- Australia
- Belgium
- The Netherlands
Friedreich Ataxia Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status
- The report reviews top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reasons for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
PTC Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Clinilabs Inc
Ixchel Pharma LLC
Larimar Therapeutics Inc
Neurocrine Biosciences Inc
Ataxia UK
Horizon Therapeutics Plc
Reata Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the Friedreich Ataxia clinical trials market?
The key regions in the Friedreich Ataxia clinical trials market are North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America, among others.
-
Which are the key countries in the Friedreich Ataxia clinical trials market?
The key countries in the Friedreich Ataxia clinical trials market are the US, Italy, France, Spain, Austria, Germany, the UK, Australia, Belgium, and the Netherlands.
-
Who are the key sponsor types in the Friedreich Ataxia clinical trials market?
The key sponsor types in the Friedreich Ataxia clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the Friedreich Ataxia clinical trials market?
The leading sponsors in the Friedreich Ataxia clinical trials market are Santhera Pharmaceuticals Holding AG, PTC Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Clinilabs Inc, Ixchel Pharma LLC, Larimar Therapeutics Inc, Neurocrine Biosciences Inc, Ataxia UK, Horizon Therapeutics Plc, and Reata Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.